What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to stimulate the body's natural production of growth hormone. Two forms are commonly discussed in research: CJC-1295 with DAC (Drug Affinity Complex), which has a prolonged half-life, and CJC-1295 without DAC (often called MOD GRF 1-29), which has a much shorter duration of action.
How It Works
CJC-1295 binds to GHRH receptors in the anterior pituitary, increasing pulsatile growth hormone secretion. This leads to increased production of insulin-like growth factor-1 (IGF-1), supporting research into recovery, body composition, protein synthesis, tissue repair, and healthy aging while preserving the body's natural hormonal feedback mechanisms.
Potential Benefits Being Studied
Researchers have investigated CJC-1295 for lean muscle preservation, reduction in body fat, exercise recovery, improved sleep quality, connective tissue repair, age-related decline in GH production, bone metabolism, and overall metabolic health. Many applications remain investigational.
Typical Research Dosing
Published research protocols differ depending on whether the DAC or non-DAC formulation is used. Longer-acting DAC formulations are generally studied less frequently than shorter-acting versions. There is no universally accepted dosing regimen outside controlled research.
Administration and Timing
Most research uses subcutaneous injection. Non-DAC protocols often evaluate administration around natural GH pulses, while DAC formulations are typically investigated with less frequent dosing because of their extended half-life.
Possible Side Effects
Reported side effects include headache, flushing, water retention, injection-site irritation, tingling sensations, fatigue, and temporary increases in IGF-1. Long-term safety continues to be evaluated.
Contraindications and Precautions
Because CJC-1295 stimulates the growth hormone axis, caution is appropriate in individuals with active malignancy, uncontrolled endocrine disease, or elevated IGF-1 levels. Consultation with a qualified healthcare professional is appropriate before therapies affecting GH pathways are considered.
Bottom Line
CJC-1295 remains one of the best-known GHRH analogues in peptide research. Its ability to stimulate endogenous growth hormone production, particularly when paired with growth hormone secretagogues in research settings, continues to make it a valuable compound for studying recovery, body composition, and healthy aging.
Educational Reminder
This document is intended for educational purposes only and should not replace individualized medical advice.